


SLC3037

Cat. No.:	HY-163358
Molecular Formula:	C ₂₉ H ₃₅ N ₇ OS
Molecular Weight:	529.7
Target:	NOD-like Receptor (NLR); NEKs
Pathway:	Immunology/Inflammation; Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases ^[1] .	
IC ₅₀ & Target	NLRP3	NEK7
In Vitro	SLC3037 (1-10 μM, 5 h) inhibits the IL-1β induced by LPS and MSU dose-dependently in BMDMs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Park K, et al. A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout. *Front Immunol.* 2024 Feb 2;14:1307739.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA